Dupont Capital Management Corp bought a new position in shares of Veracyte Inc (NASDAQ:VCYT) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 62,571 shares of the biotechnology company’s stock, valued at approximately $787,000. Dupont Capital Management Corp owned 0.15% of Veracyte as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its stake in Veracyte by 15.7% in the 3rd quarter. Wells Fargo & Company MN now owns 43,349 shares of the biotechnology company’s stock valued at $415,000 after purchasing an additional 5,885 shares during the period. Meeder Asset Management Inc. raised its holdings in shares of Veracyte by 79.8% during the 3rd quarter. Meeder Asset Management Inc. now owns 16,178 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 7,182 shares in the last quarter. Teachers Advisors LLC grew its position in Veracyte by 21.1% during the 3rd quarter. Teachers Advisors LLC now owns 50,146 shares of the biotechnology company’s stock worth $479,000 after acquiring an additional 8,740 shares during the last quarter. Engineers Gate Manager LP grew its position in Veracyte by 38.4% during the 3rd quarter. Engineers Gate Manager LP now owns 34,214 shares of the biotechnology company’s stock worth $327,000 after acquiring an additional 9,495 shares during the last quarter. Finally, Essex Investment Management Co. LLC grew its position in shares of Veracyte by 3.5% in the 3rd quarter. Essex Investment Management Co. LLC now owns 315,286 shares of the biotechnology company’s stock worth $3,011,000 after buying an additional 10,531 shares during the last quarter. 88.69% of the stock is owned by institutional investors and hedge funds.
VCYT has been the subject of a number of recent research reports. BTIG Research lifted their price objective on Veracyte to $17.00 and gave the company a “buy” rating in a research note on Friday, January 4th. Janney Montgomery Scott lowered Veracyte from a “buy” rating to a “neutral” rating and set a $12.30 price target for the company. in a report on Thursday, November 29th. William Blair reaffirmed an “outperform” rating on shares of Veracyte in a research note on Tuesday, October 30th. BidaskClub upgraded Veracyte from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 22nd. Finally, Zacks Investment Research downgraded Veracyte from a “buy” rating to a “hold” rating in a research report on Saturday, January 19th. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. Veracyte presently has a consensus rating of “Buy” and a consensus price target of $15.08.
Shares of Veracyte stock opened at $18.30 on Thursday. The company has a market cap of $741.86 million, a PE ratio of -20.11 and a beta of 0.99. The company has a debt-to-equity ratio of 0.32, a quick ratio of 8.81 and a current ratio of 9.14. Veracyte Inc has a 1-year low of $5.23 and a 1-year high of $19.44.
Veracyte, Inc operates as a genomic diagnostics company in the United States. It uses genomic technology to resolve diagnostic uncertainty. The company offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.
Featured Article: What is a Stop Order?
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.